A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

780

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Rituximab
DRUG: Lenalidomide
DRUG: Obinutuzumab

Sponsor

BeiGene